Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 6/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229385 | 1.00 | KAT2B (0.45) | KAT2BLTA4HEPHX2DRD3JAK2 | |
| SCHEMBL1708335 | 0.95 | KAT2B (0.51) | KAT2BKDM4EKMT2ASIGMAR1 | |
| SCHEMBL1708336 | 0.95 | KAT2B (0.51) | KAT2BKDM4EKMT2ASIGMAR1 | |
| SCHEMBL4225920 | 0.94 | SIGMAR1 (0.47) | LTA4HSIGMAR1HDAC1HDAC8HDAC6 | |
| SCHEMBL5169737 | 0.94 | SIGMAR1 (0.47) | LTA4HSIGMAR1HDAC1HDAC8HDAC6 | |
| SCHEMBL4225925 | 0.94 | SIGMAR1 (0.47) | LTA4HSIGMAR1HDAC1HDAC8HDAC6 | |
| SCHEMBL1708477 | 0.92 | KAT2B (0.41) | KAT2BLTA4HKMT2A | |
| SCHEMBL1708479 | 0.92 | KAT2B (0.41) | KAT2BLTA4HKMT2A | |
| SCHEMBL4228350 | 0.91 | JAK2 (0.50) | KAT2BJAK2JAK3KDM4ESIGMAR1 | |
| SCHEMBL4228357 | 0.91 | JAK2 (0.50) | KAT2BJAK2JAK3KDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | KAT2B 16/4885LTA4H 1204/4885EPHX2 3290/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | KAT2B 19/4885LTA4H 1587/4885EPHX2 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.